impaired glucose tolerance, obstructs hepatic insulin signaling, and promotes adipose tissue inflammation of mice maintained on a high-fat diet. 14, 17 Consistently, numerous case-control and longitudinal human studies have shown that increased TMAO levels are associated with an increased risk of incident major adverse cardiovascular events. [18] [19] [20] [21] [22] [23] However, most prior studies were conducted in Western countries. Research on Asian populations, and especially populations from Asian developing countries, where dietary habits are different from that of Western countries, is limited. In addition, all published studies define cardiovascular events as a composite of death, myocardial infarction, and stroke. Whether TMAO level is associated with the risk of stroke remains unknown.
Hypertension is one of the most important risk factors for stroke. 4, 5 Using data from the CSPPT (China Stroke Primary Prevention Trial), 24 we conducted a nested case-control study to examine the longitudinal association between baseline serum TMAO concentrations and the risk of incident first stroke in Chinese hypertensive patients without a history of stroke or myocardial infarction during a period of 4.5 years of follow-up.
Materials and Methods
Our article adheres to the American Heart Association journal implementation of the Transparency and Openness Promotion Guidelines. The parent study (the CSPPT) and the current study were approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (Federalwide Assurance Number: 00001263). All participants provided written informed consent. The data, analytic methods, and study materials that support the findings of this study will be available from the corresponding author on request, after the request is submitted and formally reviewed and approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University.
Study Participants
The sample population for this study was drawn from the CSPPT. Details on the study design, study protocol, and major results of the CSPPT have been reported elsewhere. 24 Briefly, the CSPPT was a randomized, double-blind clinical trial conducted from May 19, 2008 , to August 24, 2013 , in 32 communities in China. Eligible participants were men and women aged 45 to 75 years who had hypertension, defined as seated resting systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (BP) ≥90 mm Hg at both the screening and recruitment visits or who were taking antihypertensive medications. The major exclusion criteria included history of physician-diagnosed stroke, myocardial infarction (MI), heart failure, coronary revascularization, or congenital heart disease.
A total of 20 702 eligible participants were randomly assigned, in a 1:1 ratio, to 1 of 2 treatment groups: a daily oral dose of 1 tablet containing 10 mg enalapril and 0.8 mg folic acid (the enalapril-folic acid group) or a daily oral dose of 1 tablet containing 10 mg enalapril only (the enalapril-only group). Participants were followed up every 3 months.
Study Outcomes
The primary outcome was a first nonfatal or fatal stroke (ischemic or hemorrhagic), excluding subarachnoid hemorrhage and silent stroke. The secondary outcomes included first ischemic stroke (fatal or nonfatal) and first hemorrhagic stroke (fatal or nonfatal).
All of the outcomes were reviewed and adjudicated according to standard criteria by an independent Endpoint Adjudication Committee.
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Nested Case-Control Study
Using data from the CSPPT, we conducted a nested case-control study of the 637 incident stroke cases and matched them with 637 controls within this cohort. Controls were randomly chosen from the baseline CSPPT participants who did not develop stroke during the follow-up. Controls were matched for age (±1 year), sex, treatment group, and study site with the cases on a 1:1 ratio. After excluding those with missing TMAO data, a total of 622 incident cases and 622 matched controls were included in the current analysis ( Figure I in the online-only Data Supplement).
Laboratory Assays
Overnight fasting venous blood samples of all participants were obtained from each subject at baseline. Routine biochemical measurements were performed on an automatic clinical analyzer (Beckman Coulter) at the core laboratory of the National Clinical Research Center for Kidney Disease, Guangzhou, China. Serum folate was measured at a commercial laboratory with the use of a chemiluminescent immunoassay (New Industrial, Shenzhen). The estimated glomerular filtration rate (eGFR) was calculated with the use of the Chronic Kidney Disease Epidemiology Collaboration equation.
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Quantification of TMAO, Choline, and L-Carnitine
Serum concentrations of TMAO, choline, and L-carnitine were quantified by stable isotope dilution liquid chromatography tandem mass spectrometry (6460 Series Triple Quadrupole LC/MS; Agilent, CA) as described previously. 9 A volume of 50 μL of either the serum sample or standards were combined with 100 μL of acetonitrile containing 10 μM of internal standards (d9-choline, d9-carnitine, and d9-TMAO) and then centrifuged at 14 000 g for 15 minutes. After an additional centrifugation step, the supernatant was analyzed after injection into a normal-phase silica column (2.1×50 mm, 2.7 μm) and equilibrated with 19% solution A (10 mmol/L ammonium formate and 0.1% formate acid in water) and 81% solution B (acetonitrile) under isocratic elution with the flow rate of 0.3 mL/min.
Statistical Analysis
There were missing values on serum total cholesterol (TC; n=31), smoking status (n=1), serum total homocysteine (n=24), folate (n=17), eGFR (n=31), and fasting glucose (n=31) at baseline. Multiple imputations were used to handle missing values in the outcome analyses. Baseline characteristics and time-averaged BP during the treatment period are presented as means (SD) or medians (25th-75th percentile) for continuous variables and proportions for categorical variables. Differences in baseline characteristics between cases and controls were compared using conditional logistic regression for categorical variables and generalized paired t tests for continuous variables.
Odds ratios (ORs) of first stroke in relation to serum concentrations of TMAO (continuous and categorical variables) were calculated using conditional logistic regression models, 26 without and with adjustment for body mass index, smoking status, SBP, fasting glucose, TC, eGFR, total homocysteine, folate, choline, and L-carnitine, as well as time-averaged SBP during the treatment period. Finally, possible modifications on the relation of TMAO levels as a binary variable (<1.79 μmol/L [tertile 1] versus ≥1.79 μmol/L [tertile 2-3]) with stroke were evaluated by stratified analyses and by interaction testing.
A 2-tailed P <0.05 was considered to be statistically significant. R software, version 3.4.3 (https://www.r-project.org), and Empower R (www.empowerstats.com/en/; X&Y Solutions, Inc, Boston, MA) were used for all data analyses.
Results
Study Participants and Baseline Characteristics
In this study, we analyzed 622 first stroke cases, comprising 502 cases of first ischemic stroke, 118 cases of first hemorrhagic stroke, and 2 cases of first uncertain type of stroke.
Baseline characteristics of all participants are summarized in Tables 1 and 2 . Median values of serum TMAO concentrations in stroke and control subjects were 2.5 μmol/L (interquartile range, 1.6-4.0) and 2.3 μmol/L (interquartile range, 1.4-3.7), respectively. Patients with stroke had higher body mass index, TC, fasting glucose, choline levels, higher SBP and diastolic BP levels both at baseline and during the treatment period, lower folate levels, a higher prevalence of diabetes mellitus, and were more likely to be smokers than control subjects (Table 1) . When all the participants were stratified into tertiles based on their baseline serum TMAO concentrations, participants with higher TMAO levels tended to be older; had higher fasting glucose, TC, total homocysteine, and choline levels; lower eGFR levels; and a higher prevalence of diabetes mellitus (Table 2) .
Furthermore, we have evaluated the association between TMAO and BP levels in all participants ( (Table III in the online-only Data Supplement). Among the case group, the time-averaged BP during the treatment period was similar across the TMAO tertiles, but the baseline BP levels were lower in participants in TMAO tertile 2 to 3 compared with those in tertile 1 (Table II in 
Association of Baseline TMAO Levels With the Risk of First Stroke
The study was conducted from May 2008 to August 2013. The association between baseline natural log transformed TMAO levels and the risk of first stroke is graphically displayed in Figure II in the online-only Data Supplement.
Overall, after fully adjusting for choline, L-carnitine, and other important covariates, including baseline SBP and timeaveraged SBP during the treatment period, the risk of first stroke increased with each increment in TMAO level (per natural log [TMAO] increment: OR, 1.22; 95% CI, 1.02-1.46). When TMAO was assessed as tertiles, compared with the lowest tertile (<1.79 μmol/L) of serum TMAO levels, the adjusted ORs (95% CI) for first stroke in the middle (1.79-<3.19 μmol/L) and highest (≥3.19 μmol/L) tertiles were 1.27 (0.91-1.77) and 1.43 (1.02-2.01; P for trend, 0.042), respectively. When combined, the patients in the upper tertiles (tertile 2-3 [≥1.79 μmol/L]: OR, 1.34; 95% CI, 1.00-1.81; P=0.049) had a 34% higher risk of first stroke than those in the lowest tertile (<1.79 μmol/L; Table 3 ).
Consistently, a significantly higher risk of first hemorrhagic stroke (OR, 2.22; 95% CI, 1.03-4.75) and a higher trend of first ischemic stroke (OR, 1.29; 95% CI, 0.93-1.80) were found in participants in TMAO tertile 2 to 3 compared with those in tertile 1 (Table 3) . However, no significant association between either choline (P=0.812) or L-carnitine (P=0.865) with the risk of first stroke was found (Table IV in the online-only Data Supplement).
Stratified Analyses by Important Covariables
Stratified analyses were performed to assess the association between serum TMAO levels (≥1.79 versus <1.79 μmol/L) and the risk of first stroke, first ischemic stroke, and first hemorrhagic stroke in various subgroups (Figure; Figures III and IV in the online-only Data Supplement). We observed an interaction between serum TMAO and folate levels (≥7.7 [median] versus <7.7 ng/mL; to convert ng/mL to nmol/L, divide by 2.266) on first stroke (P for interaction, 0.030; Figure) or first ischemic stroke (P for interaction, 0.015; Figure III in the online-only Data Supplement) but not for first hemorrhagic stroke (P for interaction, 0.928; Figure IV in the online-only Data Supplement). Higher serum TMAO levels were significantly associated with a higher risk of first stroke (OR, 1.85; 95% CI, 1.24-2.78) and first ischemic stroke (OR, 2.07; 95% CI, 1.27-3.35) in those with folate ≥7.7 ng/mL.
Other variables including SBP, total homocysteine, TC, eGFR, and diabetes mellitus at baseline, as well as 
Discussion
Previous studies have shown that elevated TMAO concentrations are associated with an increased risk of incident major adverse cardiovascular events defined as a composite of death, myocardial infarction, and stroke, but whether TMAO levels can predict the risk of stroke remains unknown. In the current study, we examined the association between baseline TMAO concentrations and the risk of first stroke in a hypertensive Chinese population. We demonstrated that higher TMAO levels were associated with increased risk of first stroke, even after adjustment for choline, L-carnitine, and other important covariates, including baseline SBP and time-averaged SBP during the treatment period. To our knowledge, this is the first and largest study by far to evaluate the relationship of serum TMAO concentrations with risk of first stroke. Shafi et al 27 reported that TMAO had a linear increase in risk with cardiovascular mortality in white hemodialysis patients, but not in black patients, suggesting the association between TMAO and outcomes might differ by race and ethnic groups. Recently, a meta-analysis, including 19 prospective studies, found that elevated concentrations of TMAO and its precursors (L-carnitine, choline, or betaine) were associated with increased risks of major adverse cardiovascular events and all-cause mortality independently of traditional risk factors. 28 The pooled risk of TMAO was stronger than that of its precursors. However, most of the study participants were from Europe and the United States, and the majority included in the analysis was white. Therefore, it is necessary to further examine whether this association exists in different race and ethnic groups, especially in Asians. Our study is the first to reveal a significant association between TMAO concentrations and the risk of first stroke in hypertensive patients. *Values are presented as mean (SD). †Except for time-averaged SBP and DBP during the treatment period. ‡Diabetes mellitus was defined as having a history of diabetes mellitus or under glucose-lowering therapy or a fasting blood glucose concentration ≥7.0 mmol/L at baseline. §Values are presented as median (interquartile range).
In addition, we found that the median TMAO concentration of Chinese hypertensive patients is 2.4 μmol/L (interquartile range, 1.5-3.8), which is lower than that of patients with cardiovascular diseases. [29] [30] [31] Whether the lower concentration of TMAO is because of the effects of a Chinese diet or lifestyle remains to be further investigated. 32 Moreover, in the current study, a significant increased risk of first stroke was observed when TMAO was ≥1.79 μmol/L, which is also lower than the concentration threshold for predicting the composite of cardiovascular events in patients with cardiovascular diseases.
18, 31 The hypertensive participants included in the CSPPT had no preexisting stroke or myocardial infarction and a low-frequency use of cardiac and vascular protective drugs. Therefore, our results are less likely to be confounded by medications and vascular diseases.
More interestingly, our study demonstrated that TMAO has a stronger association with hemorrhagic stroke than ischemic stroke. The pathological changes in the small vessels leading to hemorrhagic stroke include lipohyalinosis, fibrinoid necrosis, and microaneurysm formation in the walls of small arteries. 33, 34 Endothelial dysfunction, in part, resulting from excessive production of reactive oxygen species and 
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inflammation, is an important mechanism of cerebrovascular damage. 34, 35 Recent studies have shown that TMAO promotes vascular inflammation and endothelial cell dysfunction via various signaling pathways, 36, 37 raising the possibility that TMAO may play a role in hemorrhagic stroke. Nevertheless, because of relatively small sample size of hemorrhagic stroke, our findings need to be further confirmed.
Another interesting finding of the present study is that baseline folate concentrations modified the effect of TMAO on the incidence of first stroke, as well as first ischemic stroke. As shown in Figure, those with low folate and high TMAO had the highest rate of stroke, whereas those with high folate and low TMAO had the lowest rate of stroke. If further confirmed, maintaining both high folate and low TMAO levels could be a highly effective strategy for preventing stroke.
Previous studies have shown that plasma levels of choline or L-carnitine are associated with TMAO levels, as well as an increased risk of cardiovascular events in patients with cardiovascular disease. 29, 38 However, in the present study, no association between choline or L-carnitine with stroke was observed in Chinese hypertensive patients (Table IV in the online-only Data Supplement). Moreover, no association between TMAO and choline or L-carnitine was observed in Chinese hypertensive patients (Table V in the online-only Data Supplement). Because only dietary choline and L-carnitine can be metabolized to trimethylamine by the gut microbiota, 10 one explanation for our findings might be that Chinese diets contain less choline-and carnitine-rich foods than Western diets and thereby contribute less to TMAO production. 13, 14 Our study has several limitations. First, the participants of the current study were hypertensive patients with a mean age of ≈62 years, whether our findings are directly applicable to younger hypertensive patients or to the general population needs further investigation. Second, TMAO was measured at only a single time point, and we did not have dietary history to assess the impact of diet on TMAO levels. Third, we did not have any information on gastrointestinal symptoms or antibiotic use before blood sampling. Fourth, considering costs and efficiency, we chose a case-control study design; larger prospective cohorts are needed to confirm our findings. Finally, although extensive adjustments for known factors were made and stratified analyses were conducted, we did not match cases and controls by BP levels and other potential confounding factors in our current study. However, there were no differences in baseline Figure. Stratified analyses of the association between trimethylamine N-oxide (TMAO; ≥1.79 vs <1.79 μmol/L) and first stroke.* Diabetes mellitus was defined as having a history of diabetes mellitus or under glucose-lowering therapy or a fasting blood glucose concentration ≥7.0 mmol/L at baseline. *Adjusted for choline, L-carnitine, systolic blood pressure (SBP), body mass index, fasting glucose, total cholesterol, estimated glomerular filtration rate (eGFR), total homocysteine, folate, and smoking status at baseline and time-averaged SBP during the treatment period. OR indicates odds ratio.
BP or time-averaged BP during the treatment period across the tertiles of TMAO in all participants and control group. Among the case group, the time-averaged BP during the treatment period was similar across the TMAO tertiles, but the baseline BP levels were lower in participants in TMAO tertile 2 to 3 compared with those in tertile 1. Of note, further adjustment for baseline SBP and time-averaged SBP during the treatment period did not substantially change the association between TMAO and the risk of first stroke. Furthermore, neither baseline SBP nor time-averaged SBP during the treatment period significantly modified the detrimental effects associated with higher TMAO levels and the risk of first stroke. Taken together, our data suggest that our observed TMAO-first stroke risk association was likely to be independent of the BP differences between cases and controls. However, future studies are needed to verify our results and further examine the underlying mechanisms.
Summary
Our study demonstrated a significant association of higher TMAO levels with the risk of first stroke in hypertensive patients. Our finding, if further confirmed, calls for a carefully designed clinical trial to further evaluate the role of higher TMAO levels in outcomes in hypertensive patients.
